Literature DB >> 33167325

Clinical Health Care during the COVID-19 Pandemic.

Marco Luigetti1,2, Giovanni Frisullo1,2.   

Abstract

In December 2019, the current outbreak of the new Coronavirus 19 (CoV) was identified in Wuhan, China, and then quickly spread over the world [...].

Entities:  

Keywords:  COVID-19; SARS-CoV2; healthcare system; muscle; neurological disorders; precision medicine; stroke

Year:  2020        PMID: 33167325      PMCID: PMC7694375          DOI: 10.3390/jcm9113559

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


In December 2019, the current outbreak of the new Coronavirus 19 (CoV) was identified in Wuhan, China, and then quickly spread over the world. Europe has been involved since February 2020, Italy being the first country [1]. Patients with the new CoV have symptoms similar to those of severe acute respiratory syndrome CoV (SARSCoV) spread in 2002–2004: indeed, both viruses share the same receptor, angiotensin-converting enzyme 2 [2]. For this reason, the new virus was named SARS-CoV-2, and in February 2020, the World Health Organization (WHO) named it coronavirus disease 2019 (COVID-19) [3]. Infection in humans often leads to severe clinical manifestations and high mortality [3]. Several studies have described the clinical features: the disease often manifests with flu-like symptoms, and pulmonary complications are the main feature, but various clinical manifestations involving different organs or systems can be associated [3,4]. In general, extra-pulmonary signs or symptoms appear with the progression of the disease, but in some cases may represent the onset [4]. Viral tropism and host immune responses may explain these diverse manifestations, but the precise mechanisms have not been elucidated [5]. Numerous hematologic complications of SARS-CoV-2 infection have been reported: lymphopenia, coagulation disorders, increased venous thromboembolism, etc. [6]. Cardiac complications are common (~20–25%): in older patients with chronic comorbidities (e.g., arterial hypertension, diabetes, cardiac and cerebrovascular disorders), the prevalence and risk of death of severe COVID-19 are higher [7]. Gastrointestinal symptoms can be the onset of COVID-19, and they can precede respiratory manifestations of disease by 1–2 days [8]. Acute kidney injury is a frequent complication: direct infection by SARS-COV-2 with tubular injury, pigment casts due to rhabdomyolysis, endothelial damage, glomerular thrombi, cytokine storm and/or hemodynamic changes due to severe sepsis and multiorgan failure could be the causes [9]. The cutaneous manifestations are quite varied and occur frequently (>20%): morbilliform (maculopapular), urticarial, vesicular, pernio/chilblains-like and necrotic/livedoid are the most frequently detected lesions [10]. Finally, neurological manifestations of COVID-19 are frequent, being reported in about one third of patients: symptoms and signs may involve the nervous system at all levels, from the brain to muscle [11]. Considering the rampage through the body produced by the SARS-COV-2, the greatest COVID-19 impact was on the healthcare system, which has had to face new challenges due to unexpected and more severe clinical pictures with a multiorgan involvement. Moreover, the COVID-19 pandemic has had a different impact on the in-hospital and pre-hospital performance indicators of many care pathways. On the other hand, the COVID-19 pandemic and the resulting lockdown profoundly changed the lives of people everywhere and influenced attitudes and behaviors. At present, COVID-19 has been declared a global pandemic, but our understanding of the disease is still limited. Given that COVID-19 patients can manifest with symptoms and signs involving the whole body, clinicians need to be involved, alert and prepared. The aim of this Special Issue is to present clinical and scientific reports that improve our understanding of strategies capable of managing and addressing the COVID-19 pandemic. Authors can provide information about specific integrated care pathways or new treatment approaches to improve the management of SARS-Cov-2 infection.
  11 in total

1.  Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia.

Authors:  Guangchang Pei; Zhiguo Zhang; Jing Peng; Liu Liu; Chunxiu Zhang; Chong Yu; Zufu Ma; Yi Huang; Wei Liu; Ying Yao; Rui Zeng; Gang Xu
Journal:  J Am Soc Nephrol       Date:  2020-04-28       Impact factor: 10.121

2.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

3.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

4.  Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study.

Authors:  Yishay Szekely; Yael Lichter; Philippe Taieb; Ariel Banai; Aviram Hochstadt; Ilan Merdler; Amir Gal Oz; Ehud Rothschild; Guy Baruch; Yogev Peri; Yaron Arbel; Yan Topilsky
Journal:  Circulation       Date:  2020-05-29       Impact factor: 29.690

5.  Assessment of neurological manifestations in hospitalized patients with COVID-19.

Authors:  M Luigetti; R Iorio; A R Bentivoglio; L Tricoli; V Riso; J Marotta; C Piano; G Primiano; L Zileri Del Verme; M R Lo Monaco; P Calabresi
Journal:  Eur J Neurol       Date:  2020-08-24       Impact factor: 6.288

Review 6.  The trinity of COVID-19: immunity, inflammation and intervention.

Authors:  Matthew Zirui Tay; Chek Meng Poh; Laurent Rénia; Paul A MacAry; Lisa F P Ng
Journal:  Nat Rev Immunol       Date:  2020-04-28       Impact factor: 108.555

7.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

9.  Hematological findings and complications of COVID-19.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Ismail Elalamy; Efstathios Kastritis; Theodoros N Sergentanis; Marianna Politou; Theodora Psaltopoulou; Grigoris Gerotziafas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2020-05-23       Impact factor: 13.265

10.  Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study.

Authors:  Lei Pan; Mi Mu; Pengcheng Yang; Yu Sun; Runsheng Wang; Junhong Yan; Pibao Li; Baoguang Hu; Jing Wang; Chao Hu; Yuan Jin; Xun Niu; Rongyu Ping; Yingzhen Du; Tianzhi Li; Guogang Xu; Qinyong Hu; Lei Tu
Journal:  Am J Gastroenterol       Date:  2020-05       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.